Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 6.28% and 9.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Perspective Therapeutics and PharmaLogic announce collaboration for the development and production of theranostics for cancer care
/PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a contract development and manufacturing organization and radiopharmaceutical...